Stoke Therapeutics (STOK) Net Income (2018 - 2026)

Stoke Therapeutics' Net Income history runs 9 years deep, the most recent figure standing at -$50.0 million for Q1 2026.

• In Q1 2026, Net Income fell 144.3% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$169.7 million (down 438.83% YoY), while the FY2025 annual figure was -$6.8 million, up 92.3% from the prior year.
• Net Income was -$50.0 million for Q1 2026 at Stoke Therapeutics, up from -$57.8 million in the prior quarter.
• In the past five years, Net Income ranged from a high of $112.9 million in Q1 2025 to a low of -$57.8 million in Q4 2025.
• Historically, Net Income has averaged -$20.7 million across 5 years, with a median of -$25.7 million in 2022.
• Biggest YoY gain for Net Income was 527.99% in 2025; the steepest drop was 441.27% in 2025.
• A 5-year view of Net Income shows it stood at -$25.7 million in 2022, then dropped by 5.07% to -$27.0 million in 2023, then surged by 60.43% to -$10.7 million in 2024, then sank by 441.27% to -$57.8 million in 2025, then rose by 13.53% to -$50.0 million in 2026.
• The last three Net Income figures came in at -$50.0 million (Q1 2026), -$57.8 million (Q4 2025), and -$38.3 million (Q3 2025), per Business Quant data.